Boehringer Ingelheim Highlights Asia’s Emergence as a Global Animal Health R&D Engine
INGELHEIM, Germany — Shashank Deshpande, Member of the Board of Managing Directors and Head of the Animal Health Business Unit at Boehringer Ingelheim, highlighted the changing global landscape of veterinary innovation. Speaking on industry developments, Deshpande emphasized that Western pharmaceutical markets no longer hold an exclusive monopoly on cutting-edge animal health research, pointing to Asia’s rapidly expanding R&D ecosystem as a primary growth engine for next-generation biologics and therapeutics.
The Rise of Asian Veterinary Biopharma Ecosystems
Driven by substantial capital investment, modern manufacturing infrastructure, and specialized scientific talent, countries like China, South Korea, and Singapore are rapidly scaling their veterinary research platforms.
Deshpande noted that Asian research hubs are excelling in several key areas:
-
Targeted Biologicals & Vaccines: Rapid development of novel viral-vector and mRNA vaccines targeting high-consequence swine and poultry pathogens.
-
Companion Animal Monoclonal Antibodies: Accelerated translational pipelines focusing on novel therapeutic targets for canine and feline chronic pain, oncology, and inflammatory conditions.
-
AgTech & Digital Health Integration: Early adoption of AI-driven herd monitoring, digital diagnostics, and biosecurity analytics.
